JWJacob Wilson

Jacob Wilson

*This is an algorithmically generated author record based on publicly available information.

Jacob Wilson has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Impact of Hyperarch Fascia Training on Perceived Ankle Instability and Vertical Jump Performance in Physically Active Men and Women

    by Kenneth B. Hawkins, Chong Xie, Cristal Abreu Matias, Eric M. Sikorski, Gabriel J. Wilson, Charlie Ottinger, Ryan Lowery, Jacob M. Wilson

    Chronic ankle instability (CAI) is a prevalent musculoskeletal condition that impairs physical performance and increases reinjury risk; yet, training programs emphasizing fascia-targeted techniques remain an understudied rehabilitation strategy. The purpose of this study was to examine the effects of 12 weeks of a multicomponent training intervention emphasizing fascia-targeted techniques (Hyperarch Fascia Training (HFT)) on perceived ankle instability and function, and vertical jump performance in individuals with CAI. In this decentralized, randomized controlled trial, 66 participants were randomized (HFT n = 44, CON n = 22), with 43 participants completing the study and being analyzed (HFT n = 22; CON n = 21). Selected subjects confirmed perceived ankle instability (CAIT score ≤ 25) and were assigned to either a structured, multicomponent HFT program with various foot and ankle strengthening exercises, or a passive control condition instructed to maintain activities of daily living. The HFT group experienced disproportionately higher attrition (n = 22 excluded from analysis) than CON (n = 1 excluded from analysis due to becoming unresponsive). The reasons for attrition in the HFT group were due to becoming unresponsive (n = 13), self-reported difficulty with the protocol (n = 3), scheduling conflicts (n = 3), or adverse events (n = 3, reported as moderate). Outcomes were assessed at baseline, week 8, and week 12 using the Cumberland Ankle Instability Tool (CAIT) (primary outcome), Foot and Ankle Ability Measure (FAAM) (primary outcome), countermovement jump (CMJ) (secondary outcome), and Short Form Health Survey 12 (SF-12) (exploratory outcome). The HFT group demonstrated significantly greater improvements in CAIT scores compared to CON (group × time interaction p = 0.008), with large within-group effect sizes in the HFT group relative to baseline (d = 1.49 and 1.54, at weeks 8 and 12, respectively). Significant group × time interactions also favored HFT for CMJ jump height (p = 0.017) and flight time (p = 0.005) (co-secondary outcomes), as well as the CMJ algorithmic derivatives of mean velocity (p = 0.001) and take-off velocity (p = 0.008) (exploratory outcomes). No significant group × time interactions were observed for FAAM ADL or Sport subscales. Significant group × time interactions were found for SF-12 survey results for Physical Function (p = 0.045), Limits due to Physical Health (p = 0.030) and General Health (p = 0.043), with CON tending to decline over time and HFT tending to improve. The HFT group was higher than CON on Physical Function at Week 8 (d = 1.04, p = 0.009), and on Perceived Pain at Week 12 (d = 0.88, p = 0.047). Overall, these findings suggest that a multicomponent fascia-centered training program may represent a viable intervention for improving perceived ankle stability and increasing the explosive vertical jump performance in individuals with CAI.

  • Open Access

    Four Weeks of CreaSol®Tyrosol Plus Creatine Supplementation Enhances Training Volume and Strength Endurance: A Randomized, Double-Blind, Placebo-Controlled Trial

    by Eric M. Sikorski, Tony M. Zavala, Kenneth B. Hawkins, Gabriel J. Wilson, Charlie Ottinger, Ryan Lowery, Jacob M. Wilson

    Tyrosol, a phenolic compound derived from olive products, exhibits anti-inflammatory, neuroprotective, and cardiometabolic properties, whereas creatine is a well-established ergogenic aid with documented benefits for muscular performance and emerging evidence for cognitive support. This 5-week randomized, double blind, placebo-controlled trial examined the effects of Tyrosol, creatine, their combination, and placebo on resistance and aerobic exercise performance and psychomotor vigilance in healthy adults. Participants (n = 48; 18–50 years) consumed their assigned supplement for 4 weeks, after which changes in upper and lower body strength, submaximal resistance performance, aerobic capacity, lactate responses, plyometric performance, and acute cognitive function were assessed. The Tyrosol + Creatine condition produced the most consistent improvements in upper body resistance performance, particularly for higher load, higher volume bench press work. In contrast, neither the Tyrosol-alone group, the creatine-alone group, nor the placebo group achieved this effect, which suggests there is a synergistic effect between Tyrosol and creatine. No significant effects were observed for intermediate resistance loads, isometric lower body strength, grip strength, aerobic endurance, lactate responses, plyometric outcomes, or acute psychomotor vigilance. Collectively, these findings support the use of short-term co-supplementation with Tyrosol and low-dose creatine (without a loading phase) as a potentially beneficial strategy to enhance upper-body training quality in specific tests and improve upper-body strength endurance.

  • Open Access

    A randomized controlled trial to assess the effectiveness of a mobile application-based lifestyle change program (FASTer Way) on body composition, biochemical and hematological health markers, body image, and self-esteem in overweight women

    by Charlie R. Ottinger, Raad H. Gheith, Matthew H. Sharp, Justine M. Davis, Ryan P. Lowery, Jacob M. Wilson

    Background: Numerous mobile phone applications have been developed with the goal of producing behavior changes that lead to weight loss and enhanced health. However, the evidence basis for these applications is often lacking, which renders them ineffective for altering health behaviors. Therefore, the purpose of this study was to examine the potential benefits of a novel mobile application, The FASTer Way to Fat Loss® (FW). Methods: Forty-two overweight, but otherwise healthy women were recruited for this parallel study and randomly assigned to an exercise and nutrition education only control (CON, n=21) or an integrated mobile application group (FW, n=21), which included exercise training and dietary modifications that were overseen by an individually assigned coach. Both groups were assessed at baseline and 6 weeks post-intervention for body composition, blood health indices, and multiple questionnaires for self-esteem and body image. Absolute mean differences within and between groups were measured using unpaired t-tests with statistical significance set at PResults: Compared to the CON group (0.56±1.54 kg), the FW group significantly reduced total mass (−1.21±1.82 kg; P=0.002), fat mass (0.42±1.38 vs. −1.45±1.23 kg; Pvs. −1.24%±1.32%; P=0.001), and body mass index (0.24±0.59 vs. −0.46±0.60 kg/m2; PConclusions: An integrated, multifactorial smartphone application (FASTer Way®) elicited positive changes in body composition and total cholesterol in six-weeks. Future research should investigate these effects in other populations to better generalize these results. Trial Registration: ClinicalTrials.gov NCT05813548.


  • Open Access

    The Effects of Geranylgeraniol on Blood Safety and Sex Hormone Profiles in Healthy Adults: A Dose-Escalation, Randomized, Placebo-Controlled Trial

    by Raad Gheith, Matthew Sharp, Matthew Stefan, Charlie Ottinger, Ryan Lowery, Jacob Wilson

    Geranylgeraniol (GG), an ingredient extracted from the South American annatto plant, has been shown to benefit bone and muscle health, is crucial in the biosynthesis of menaquinone-4 and coenzyme Q10, and has pain and inflammation reduction activities. However, no known studies to date have demonstrated the safety and impact of GG supplementation in humans. This 8-week, randomized, placebo-controlled, dose-escalated trial was conducted to determine the effect of GG on blood safety and hormone markers in healthy adults. Sixty-six males and females between 30 and 49 years of age were supplemented with either GG or a placebo (PLA) for 8 weeks, with dose escalation from 150 mg to 300 mg occurring after 4 weeks in the treatment group. Changes in complete blood count and comprehensive metabolic panels were analyzed for whole study groups (males and females) while changes in sex hormone panels were analyzed for males and females independently. There were no significant changes in complete blood count, comprehensive metabolic panel, progesterone, estradiol, sex–hormone binding globulin, or dihydrotestosterone (p > 0.05). An exploratory analysis of testosterone levels in a subgroup of males with baseline (Pre) total testosterone < 700 ng/dL (GG = 15; PLA = 13) demonstrated a significant increase (p < 0.05) from Pre to Week 8 in total-, free-, and bioavailable testosterone (+7.5%, +15.0%, and +14.8%, respectively). This study demonstrates that GG does not significantly change the composition of blood chemistry, hematology, or sex hormone profiles in adult males or females. Given the effects observed in the exploratory analysis in a subgroup of males, GG supplementation may be beneficial for testosterone enhancement in male populations subject to low testosterone (i.e., aging males and those with late-onset hypogonadism), but further research is needed.


  • Open Access

    Assessment of the Efficacy of a Low-Dose Iron Supplement in Restoring Iron Levels to Normal Range among Healthy Premenopausal Women with Iron Deficiency without Anemia

    by Matthew W. Stefan, David M. Gundermann, Matthew H. Sharp, Brooke A. Jennings, Raad H. Gheith, Ryan P. Lowery, Tieraona LowDog, Somsuvra B. Ghatak, Jose Barbosa, Jacob M. Wilson

    (1) Background: Iron deficiency without anemia (IDWA) is a prevalent health concern in premenopausal women. Oral supplementation of iron may be a viable solution to improve blood-iron status in women; however, the effects of a high-dose iron-supplement regimen have been associated with gastrointestinal side effects. Therefore, the purpose of the present study was to evaluate the effectiveness of a low-dose liquid fermented iron-bisglycinate supplement (LIS) on improving blood-iron status in premenopausal women with IDWA without increasing constipation or gastrointestinal distress. (2) Methods: 85 premenopausal women with IDWA (ferritin < 70 ng/dL and hemoglobin > 11.0 g/dL) took a LIS (27 mg) or a placebo (PLA) for 8 weeks. Blood draws were taken at Wk0 and Wk8 of the study to measure serum-iron markers. In addition, surveys of gastrointestinal distress were administered at Wk0, Wk4, and Wk8 while the profile of mood states (POMS) was surveyed at Wk0 and Wk8. (3) Results: Compared to the placebo, the LIS was able to increase serum ferritin (p = 0.03), total serum iron (p = 0.03), and mean corpuscular volume (p = 0.02), while exhibiting no significant interaction in subjective gastrointestinal distress (p > 0.05). No significant effects were detected for POMS (p > 0.05). (4) Conclusions: Supplementing with LIS appears to improve blood-iron status without causing significant gastrointestinal distress in premenopausal women with IDWA.


  • Open Access

    Publisher Correction to: The Effects of Offset Loading Versus Traditional Loading in the Bench Press Exercise on Muscle Thickness and Strength in Trained Males

    by Matthew Sharp, Charlie Ottinger, Raad Gheith, Matthew Stefan, Ryan Lowery, Salvatore LoDuca, Jacob Wilson

  • Open Access

    The Effects of Offset Loading Versus Traditional Loading in the Bench Press Exercise on Muscle Thickness and Strength in Trained Males

    by Matthew Sharp, Charlie Ottinger, Raad Gheith, Matthew Stefan, Ryan Lowery, Salvatore LoDuca, Jacob Wilson

    Purpose: This study compared the effects of offset loading (OSL) versus traditional loading (TDL) in the bench press exercise on pectoral muscle thickness and bench press strength over a 4-week mesocycle. Methods: Twenty male participants aged 18–45 years with at least 5 years of bench press experience and a bench press one-repetition maximum equal to or greater than their body mass were randomly assigned to OSL and TDL groups. Before and after the 4-week mesocycle, pectoral muscle thickness was assessed via ultrasonography and muscle strength was assessed by bench press one-repetition maximum. Effects were explored with two-way mixed ANOVA and non-clinical magnitude-based inferences. Results: No group-by-time interaction was detected for any variable (P > 0.05). When compared to small magnitudes, the pectoralis major muscle thickness changes were likely greater in OSL compared to TDL for the dominant (ES = 0.70; 87% likely greater) and nondominant pectoralis (ES = 0.77; 91% likely greater) as well as the sum of both pectorals (ES = 0.80; 92% likely greater). Similarly, a likely greater effect for absolute (ES = 0.57; 82% likely) and relative (ES = 0.67; 85% likely) bench press strength was seen with OSL. Conclusion: Magnitude-based inferences interpreted here support the notion that OSL may be an advantageous training modality to enhance pectoral muscle thickness and bench press strength.


  • Open Access

    Erratum: Sharp et al. Phytoplankton Supplementation Lowers Muscle Damage and Sustains Performance across Repeated Exercise Bouts in Humans and Improves Antioxidant Capacity in a Mechanistic Animal. Nutrients 2020, 12, 1990

    by Matthew Sharp, Kazim Sahin, Matthew Stefan, Cemal Orhan, Raad Gheith, Dallen Reber, Nurhan Sahin, Mehmet Tuzcu, Ryan Lowery, Shane Durkee, et al.

    Modifications to the Main Text [...]

  • Open Access

    L-Carnitine Tartrate Supplementation for 5 Weeks Improves Exercise Recovery in Men and Women: A Randomized, Double-Blind, Placebo-Controlled Trial

    by Matthew Stefan, Matthew Sharp, Raad Gheith, Ryan Lowery, Charlie Ottinger, Jacob Wilson, Shane Durkee, Aouatef Bellamine

    L-carnitine tartrate has been shown to improve relatively short-term recovery among athletes. However, there is a lack of research on the longer-term effects in the general population. Objective: The primary objectives of this randomized double-blind, placebo-controlled trial were to evaluate the effects of daily L-carnitine tartrate supplementation for 5 weeks on recovery and fatigue. Method: In this study, eighty participants, 21- to 65-years-old, were recruited. Participants were split into two groups of forty participants each, a placebo, and a L-carnitine Tartrate group. Seventy-three participants completed a maintenance exercise training program that culminated in a high-volume exercise challenge. Results: Compared to placebo, L-carnitine tartrate supplementation was able to improve perceived recovery and soreness (p = 0.021), and lower serum creatine kinase (p = 0.016). In addition, L-carnitine tartrate supplementation was able to blunt declines in strength and power compared to placebo following an exercise challenge. Two sub-analyses indicated that these results were independent of gender and age. Interestingly, serum superoxide dismutase levels increased significantly among those supplementing with L-carnitine tartrate. Conclusions: These findings agree with previous observations among healthy adult subjects and demonstrate that L-carnitine tartrate supplementation beyond 35 days is beneficial for improving recovery and reducing fatigue following exercise across gender and age.


  • Open Access

    L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection

    by Aouatef Bellamine, Tram N. Q. Pham, Jaspreet Jain, Jacob Wilson, Kazim Sahin, Frederic Dallaire, Nabil G. Seidah, Shane Durkee, Katarina Radošević, Éric A. Cohen

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for one of the worst pandemics in modern history. Several prevention and treatment strategies have been designed and evaluated in recent months either through the repurposing of existing treatments or the development of new drugs and vaccines. In this study, we show that L-carnitine tartrate supplementation in humans and rodents led to significant decreases of key host dependency factors, notably angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and Furin, which are responsible for viral attachment, viral spike S-protein cleavage, and priming for viral fusion and entry. Interestingly, pre-treatment of Calu-3, human lung epithelial cells, with L-carnitine tartrate led to a significant and dose-dependent inhibition of the infection by SARS-CoV-2. Infection inhibition coincided with a significant decrease in ACE2 mRNA expression levels. These data suggest that L-carnitine tartrate should be tested with appropriate trials in humans for the possibility to limit SARS-CoV-2 infection.